CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality

Affiliations

¹ Istituto Europeo di Oncologia, IRCCS, and University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
² GBG Forschungs GmbH and Centre for Haematology and Oncology, Bethanien, Frankfurt, Germany.

Comment

Giuseppe Curigliano et al. Lancet Oncol. 2020 Feb.

. 2020 Feb;21(2):191-192.

doi: 10.1016/S1470-2045(19)30808-3. Epub 2019 Dec 16.

¹ Istituto Europeo di Oncologia, IRCCS, and University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
² GBG Forschungs GmbH and Centre for Haematology and Oncology, Bethanien, Frankfurt, Germany.

No abstract available

Comment on

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ, Cheng J, Bloomquist E, Sanchez J, Wedam SB, Singh H, Amiri-Kordestani L, Ibrahim A, Sridhara R, Goldberg KB, Theoret MR, Kluetz PG, Blumenthal GM, Pazdur R, Beaver JA, Prowell TM. Gao JJ, et al. Lancet Oncol. 2020 Feb;21(2):250-260. doi: 10.1016/S1470-2045(19)30804-6. Epub 2019 Dec 16. Lancet Oncol. 2020. PMID: 31859246